Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C

References

• Younossi ZM. Hepatitis C infection: a systemic disease. Clin Liver Dis. 2017;21:449–453.
   PubMed Web of Science ®Google Scholar
• Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161–176.
   PubMed Web of Science ®Google Scholar
• Spengler U. Direct antiviral agents (DAAs) – a new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2017. DOI:10.1016/j.pharmthera.2017.10.009
   PubMedGoogle Scholar
• Nahon P, Bourcier V, Layese R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017 Jan;152(1)142–156.e2.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355:2444–2451.
   PubMed Web of Science ®Google Scholar
• Soriano V, Peters MG, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis. 2009;48:313–320.
   PubMed Web of Science ®Google Scholar
• Druyts E, Lorenzi M, Toor K, et al. Network meta-analysis of direct-acting antivirals in combination with peginterferon–ribavirin for previously untreated patients with hepatitis C genotype 1 infection. Q J Med. 2014. DOI:10.1093/qjmed/hcu202.
   Google Scholar
• Benítez-Gutiérrez L, Barreiro P, Labarga P, et al. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother. 2016;17:1215–1223.
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Zappulo E, et al. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus free world? Expert Rev Anti Infect Ther. 2014;12:763–773.
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia G. A pill a day keeps HCV away. Lancet Infect Dis. 2015;15:616–617.
   PubMed Web of Science ®Google Scholar
• IDSA/AASLD. Recommendations for testing, managing, and treating hepatitis C. [ cited 2017 Oct 31]. Available from: http://www.hcvguidelines.org.
   Google Scholar
• EASL. Recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–194.
   PubMedGoogle Scholar
• Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43:1276–1292.
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Lawitz E, Poordad F. Novel treatments for chronic hepatitis C: closing the remaining gaps. Curr Opin Pharmacol. 2017;37:107–111.
   PubMed Web of Science ®Google Scholar
• Johnson S, Thompson D, Raccor B. Hepatitis C virus genotype 3: update on current and emergent therapeutic interventions. Curr Infect Dis Rep. 2017;19:22.
   PubMed Web of Science ®Google Scholar
• Esposito I, Trinks J, Hepatitis SV. C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol. 2016;12:1197–1209.
   PubMed Web of Science ®Google Scholar
• Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Daklinza (daclatasvir dihydrochloride): summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/003768/WC500172848.pdf. Accessed 2017 Oct 31.
   Google Scholar
• McCormack PL. Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection. Drugs. 2015;75:515–524.
   PubMed Web of Science ®Google Scholar
• Scola PM, Sun LQ, Wang AX, et al. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014;57:1730–1752.
   PubMed Web of Science ®Google Scholar
• McPhee F, Sheaffer AK, Friborg J, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012;56:5387–5396.
   PubMed Web of Science ®Google Scholar
• Gentles RG, Ding M, Bender JA, et al. Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem. 2014;57:1855–1879.
   PubMed Web of Science ®Google Scholar
• Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014;146:420–429.
   PubMed Web of Science ®Google Scholar
• Everson GT, Sims KD, Thuluvath PJ, et al. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver Int. 2016;36:189–197.
   PubMed Web of Science ®Google Scholar
• Kwo P, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol. 2017;67:263–271.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Poordad F, Wells J, et al. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus. Hepatology. 2017;65:1803–1809.
   PubMed Web of Science ®Google Scholar
• Ahmed AM, Doheim MF, Mattar OM, et al. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. J Med Virol. 2017. DOI:10.1002/jmv.24947.
   Web of Science ®Google Scholar
• Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96–100.
   PubMed Web of Science ®Google Scholar
• Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA. 2013;110:3991–3996.
   PubMed Web of Science ®Google Scholar
• Degasperi E, Aghemo A, Colombo M. Daclatasvir for the treatment of chronic hepatitis C. Expert Opin Pharmacother. 2015;16:2679–2688.
   PubMed Web of Science ®Google Scholar
• Pelosi LA, Voss S, Liu M. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother. 2012;56:5230–5239.
   PubMed Web of Science ®Google Scholar
• Eley T, Han YH, Huang SP, et al. Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease. Clin Pharmacol Ther. 2015;97:159–166.
   PubMed Web of Science ®Google Scholar
• Akamatsu N, Sugawara Y, Kokudo N. Asunaprevir (BMS-650032) for the treatment of hepatitis C virus. Expert Rev Anti Infect Ther. 2015;13:1307–1317.
   PubMed Web of Science ®Google Scholar
• Gentile I, Zappulo E, Buonomo AR, et al. Asunaprevir for hepatitis C: a safety evaluation. Expert Opin Drug Saf. 2015;14:1631–1646.
   PubMed Web of Science ®Google Scholar
• Germain MA, Chatel-Chaix L, Gagne B, et al. Elucidating novel hepatitis c virus/host interactions using combined mass spectrometry and functional genomics approaches. Mol Cell Proteomics. 2013;29:29.
   Google Scholar
• Friborg J, Levine S, Chen C, et al. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob Agents Chemother. 2013;57:1312–1322.
   PubMed Web of Science ®Google Scholar
• Rigat KL, Lu H, Wang YK, et al. Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase. J Biolog Chem. 2014;289:33456–33468.
   PubMed Web of Science ®Google Scholar
• Di Marco S, Volpari C, Tomei L, et al. Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biolog Chem. 2005;280:29765–29770.
   PubMed Web of Science ®Google Scholar
• Kukolj G, McGibbon GA, McKercher G, et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biolog Chem. 2005;280:39260–39267.
   PubMed Web of Science ®Google Scholar
• Gentile I, Zappulo E, Buonomo AR, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24(8):1111–1121.
   PubMed Web of Science ®Google Scholar
• Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology. 2011;54:1956–1965.
   PubMed Web of Science ®Google Scholar
• Furihata T, Matsumoto S, Fu Z, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014;58:4555–4564.
   PubMed Web of Science ®Google Scholar
• Yang SS, Kao JH. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. Hepatol Int. 2016;10:258–266.
   PubMed Web of Science ®Google Scholar
• Eley T, He B, Huang SP, et al. Pharmacokinetics of the NS3 protease inhibitor, asunaprevir (ASV, BMS-650032), in phase I studies in subjects with or without chronic hepatitis C. Clin Pharmacol Drug Dev. 2013;2:316–327.
   PubMed Web of Science ®Google Scholar
• Eley T, Garimella T, Li W, et al. Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug–drug interactions. Clin Pharmacokinet. 2015;54:1205–1222.
   PubMed Web of Science ®Google Scholar
• Gong J, Eley T, He B, et al. Characterization of ADME properties of [(14)C] asunaprevir (BMS-650032) in humans. Xenobiotica. 2016;46:52–64.
   PubMed Web of Science ®Google Scholar
• Lemm JA, Liu M, Gentles RG, et al. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother. 2014;58:3485–3495.
   PubMed Web of Science ®Google Scholar
• Sims KD, Lemm J, Eley T, et al. Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection. Antimicrob Agents Chemother. 2014;58:3496–3503.
   PubMed Web of Science ®Google Scholar
• Lok AS, Gardiner DF, Hezode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2014;60:490–499.
   PubMed Web of Science ®Google Scholar
• Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–2091.
   PubMed Web of Science ®Google Scholar
• Kumada H, Suzuki F, Suzuki Y, et al. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese HCV patients. J Gastroenterol Hepatol. 2016;31:14–22.
   PubMed Web of Science ®Google Scholar
• Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597–1605.
   PubMed Web of Science ®Google Scholar
• Poordad F, Sievert W, Mollison L, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1infection. JAMA. 2015;313:1728–1735.
   PubMed Web of Science ®Google Scholar
• Muir A, Poordad F, Lalezari JP, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C genotype 1 infection with compensated cirrhosis. JAMA. 2015;313:1736–1744.
   PubMed Web of Science ®Google Scholar
• Toyota J, Karino Y, Suzuki F, et al. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol. 2017;52:385–395.
   PubMed Web of Science ®Google Scholar
• Kao J-H, Yu M-L, Peng C-Y, et al. Daclatasvir/Asunaprevir/Beclabuvir (DCV-TRIO), all-oral, fixed-dose combination for patients with chronic HCV genotype 1. J Gastroenterol Hepatol. 2017;32:1998–2005.
   PubMed Web of Science ®Google Scholar
• Clinical Trial NCT03071133. Real-world incidence proportion of hepatic toxicity and all adverse drug reactions (ADRs) in Japanese patients receiving daclatasvir (DCV) trio therapy. [cited 2017 Dec 12]. Available at http://clinicaltrials.gov/ct2/show/NCT03071133.
   Google Scholar
• Sezaki H, Suzuki F, Hosaka T, et al. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings. Liver Int. 2017;37:1325–1333.
   PubMed Web of Science ®Google Scholar
• Hc N, Hl L, Yang H. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection. Clin Mol Hepatol. 2016;22:259–266.
   PubMed Web of Science ®Google Scholar
• McPhee F, Hernandez D, Zhou N, et al. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre- and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir. Antivir Ther. 2018;23(1):53–66.
   PubMed Web of Science ®Google Scholar
• MHLW. Asunaprevir/beclabuvir/daclatasvir approval. Internet-Doc 2017. 2017.
   Google Scholar
• MHLW. Asunaprevir/beclabuvir/daclatasvir launch. Internet-Doc 2017. 2017.
   Google Scholar
• Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology. 2010;53:39–43.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428.
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364(13):1207–1217.
   PubMed Web of Science ®Google Scholar
• Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016;64:370–380.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology. 2016;64:360–369.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–1493.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–15603.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with Ribavirin. N Engl J Med. 2014;370:1604–1614.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–1992.
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982.
   PubMed Web of Science ®Google Scholar
• Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–725.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1–13.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–2607.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354–369.
   PubMed Web of Science ®Google Scholar